The FDA approved Biogen's Alzheimer's drug. That's great news for Biogen and its shareholders, but it's also fantastic news for a competitor. Read More

One strike out could wipe away your gains. If you apply a consistent method, options can help you protect your hard-earned profits. Read More

The last few years have been rough for biotech stocks, but Amgen has been a notable exception. It's now facing new threats from biosimilars. Can it continue to outperform? Read More